VEGF signaling in cancer treatment

Daniela Sia, Clara Alsinet, Pippa Newell, Augusto Villanueva

Research output: Contribution to journalArticle


Induction of angiogenesis represents one of the major hallmarks of cancer. The growth of new vessels is crucial to provide malignant cells with an adequate supply of oxygen and nutrients. It is generally accepted that vascular endothelial growth factor (VEGF) is a major driver of the angiogenic process in physiological and pathological processes in both embryo and adult. VEGF is often found overexpressed in tumors, as well as its receptors VEGFR1 and VEGFR2. Hence, several different strategies have been designed to target VEGF signal transduction. In the last decades, multiple inhibitors have been therapeutically validated in preclinical models and several clinical trials. Neutralizing monoclonal antibodies against VEGF and small molecule tyrosine kinase inhibitors targeting VEGFRs have been shown to block its angiogenic activity, resulting in tumor vascular regression, anti-tumor effects and improvements in patient survival. However, side effects and lack of efficacy in some instances challenge the potential clinical impact of these therapies. This review examines the role of VEGF signaling in cancer and outlines the current status of anti-angiogenic therapies against VEGF pathway.

Original languageEnglish
Pages (from-to)2834-2842
Number of pages9
JournalCurrent Pharmaceutical Design
Issue number17
Publication statusPublished - 2014


  • Angiogenesis
  • Bevacizumab
  • Cancer
  • Targeted therapies
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Medicine(all)

Fingerprint Dive into the research topics of 'VEGF signaling in cancer treatment'. Together they form a unique fingerprint.

  • Cite this

    Sia, D., Alsinet, C., Newell, P., & Villanueva, A. (2014). VEGF signaling in cancer treatment. Current Pharmaceutical Design, 20(17), 2834-2842.